Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT05012033

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting — Recruiting • Respiratory / COPD / Asthma • NCT05012033.

📅 27 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05012033
Sponsor
Imperial College London
Start
2023-04-12
ClinicaliQ Trial Snapshot
  • Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting — Recruiting • Respiratory / COPD / Asthma • NCT05012033.
  • This is a pilot study to investigate serum prednisolone profiles in: Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting. Patients stepping up from or down to prednisolone therapy in association with a course….
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is a pilot study to investigate serum prednisolone profiles in: * Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting. * Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone. The study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone. The…

Eligibility Snapshot
  • : * Aged 18 - 75 years * Male or female * Participants who are otherwise healthy enough to participate, as determined by pre-study medical history * Participants who are able and willing to give written informed consent to participate in the study * Group A only: Patients requiring acute (30mg) if in the chronic use group. * Group C only: Patients started on high dose methylprednisolone (>3 day course) or prolonged courses of dexamethasone.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Guideline
Bronchiectasis (non-CF): Diagnosis and Management (NICE NG117)
Respiratory / COPD / Asthma · 27 Mar 2026
Suspect bronchiectasis in patients presenting with chronic productive cough or recurrent respiratory infections and refer for High-Resolution CT chest imaging; investigate all…
View guideline →
Clinical Brief
Norovirus cases remain high while respiratory viruses fall
Respiratory / COPD / Asthma · UKHSA · 05 Mar 2026
Norovirus circulation remains elevated despite seasonal decline in respiratory viruses, warranting continued vigilance for gastroenteritis outbreaks in healthcare and community settings Respiratory…
View brief →